Searching News Database: ProCellEx
HSMN NewsFeed - 12 Sep 2023
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
HSMN NewsFeed - 17 Dec 2009
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
HSMN NewsFeed - 1 Dec 2009
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
HSMN NewsFeed - 27 Aug 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD